2nd May 2012

New biotech collaboration opportunities for Medilink UK members

International biotechnology network One Nucleus has signed an agreement with Medilink UK to enable greater collaborative and commercial opportunities for all members.

 

The memorandum of understanding between the two leading trade bodies ensures that Medilink UK’s national medtech membership has greater access to Europe’s leading biotech network.

Signed by Harriet Fear, Chief Executive for One Nucleus and Medilink UK’s Chairman Tony Davis, this important document sets ways in which members of both organisations could benefit from increased access to knowledge, news, opportunities and market intelligence as well as awareness of important industry events.

Both Medilink UK and One Nucleus are committed to raising the international profile of companies within their sector, improving the global competiveness of their members, and encouraging the development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world.

Medilink UK’s Chairman, Tony Davis commented: “Our two organisations have natural synergy and we’re already working closely with One Nucleus to maximise the opportunities that its extensive biotech network could offer our members.”